Log In
BCIQ
Print this Print this
 

Onalta (Onalta edotreotide) (formerly OctreoTher)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionYttrium-90 radiolabeled somatostatin peptide analog
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat gastroenteropancreatic neuroendocrine tumor; Treat metastatic carcinoid tumors; Treat metastatic, progressive, somatostatin receptor-positive carcinoid cancer; Treat neuroendocrine tumors
Regulatory Designation EU - Orphan Drug (Treat gastroenteropancreatic neuroendocrine tumor)
PartnerBioMedica Life Sciences S.A.;
Novartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$10.0M

$4.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/14/2009

$10.0M

$4.4M

Undisclosed

Get a free BioCentury trial today